RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07648914, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;

    Inclusion criterion 12

    Previously treated with ADC drugs that use topoisomerase I inhibitors as the toxin or target EGFR and/or HER3;

    Exclusion criterion 1

    Previous treatment with anthracycline drugs where the equivalent cumulative dose of doxorubicin exceeds 360 mg/m²;

    Exclusion criterion 3

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

    Inclusion criterion 11

  4. Must have at least one measurable lesion as defined by RECIST v1.1;

    Inclusion criterion 10

  5. Diagnosis of another malignancy within 3 years before the first dose;

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07648914, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent form and comply with the protocol requirements;
  • No gender restrictions;
  • Age ≥ 18 years;
  • Expected survival time ≥ 3 months;
  • Patients with unresectable locally advanced, recurrent, or metastatic HR+ HER2- breast cancer;
  • Trial participants have not received systemic chemotherapy;
  • Trial participants have progressed after at least one line of endocrine therapy, etc.;
  • Documented radiographic disease progression prior to enrollment;
  • Agree to provide archived tumor tissue specimens or fresh tissue samples from the primary or metastatic lesion within 3 years;
  • Must have at least one measurable lesion as defined by RECIST v1.1;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  • Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
  • No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥ 50%;
  • Must meet required organ function levels;
  • Urinary protein ≤ 2+ or < 1000 mg/24h;
  • For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with a negative serum pregnancy result, and they must not be breastfeeding; all enrolled patients (regardless of gender) must use adequate barrier contraception throughout the treatment period and for 6 months after treatment ends.

Exclusion Criteria:

  • Previously treated with ADC drugs that use topoisomerase I inhibitors as the toxin or target EGFR and/or HER3;
  • Use of chemotherapy, biotherapy, immunotherapy, etc., within 4 weeks or 5 half-lives before the first dose;
  • Previous treatment with anthracycline drugs where the equivalent cumulative dose of doxorubicin exceeds 360 mg/m²;
  • History of severe cardiovascular or cerebrovascular diseases;
  • Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  • Prolonged QT interval, complete left bundle branch block, etc.;
  • Diagnosis of another malignancy within 3 years before the first dose;
  • Hypertension poorly controlled by two antihypertensive medications;
  • Poorly controlled blood glucose levels;
  • History of ILD requiring steroid therapy, current ILD, or grade ≥2 radiation pneumonitis, etc.;
  • Concurrent pulmonary diseases causing clinically severe respiratory function impairment;
  • Patients with active central nervous system metastases;
  • Presence of large serous cavity effusions or symptomatic serous cavity effusions, etc.;
  • Imaging findings indicating tumor invasion or encasement of the abdomen, chest, etc.;
  • Severe infection within 4 weeks before study randomization;
  • Severe, unhealed wounds, ulcers, or fractures within 4 weeks before signing the informed consent form;
  • Trial participants with clinically significant bleeding or a significant bleeding tendency within 4 weeks prior to signing the informed consent form;
  • History of inflammatory bowel disease, extensive bowel resection, etc.;
  • Patients with a history of allergy to recombinant humanized antibodies or allergy to BL-B01D1 or any of its excipients;
  • History of autologous or allogeneic stem cell transplantation;
  • Positive for human immunodeficiency virus antibodies, active hepatitis B virus infection, or hepatitis C virus infection;
  • Receipt of other unapproved clinical study drugs or treatments within 4 weeks before the first dose;
  • Trial participants planning to receive or having received live vaccines within 28 days before the first dose;
  • Other conditions deemed by the investigator to be unsuitable for participation in this clinical trial due to complications or other reasons.

Quoted from ClinicalTrials.gov, NCT07648914, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07648914, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07648914